Aytu BioScience offering 18.75M shares to raise $7.5M

Aytu BioScience offering 18.75M shares to raise $7.5M

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced it has priced an... Read More

Tuesday May 3, 2016 0 comments Tags: Aytu BioScience, Englewood, Natesto, MiOXSYS, ProstaScint, Primsol

Aytu appoints Jonathan Heath McGrael VP of sales

Aytu appoints Jonathan Heath McGrael VP of sales

ENGLEWOOD-- Aytu BioScience Inc . (OTCQB: AYTU), a specialty health care company developing treatments for urological and related conditions, announced the appointment of Jonathan Heath McGrael ... Read More

Thursday September 10, 2015 0 comments Tags: Englewood, Aytu BioScience, Jonathan Heath McGra, Josh Disbrow, ProstaScint

Aytu BioScience closes on $5.175M note financing

Aytu BioScience closes on $5.175M note financing

ENGLEWOOD-- Aytu BioScience Inc . (OTCQB: AYTU), a specialty health care company focused on developing treatments for urological and related conditions, announced it has closed on the final... Read More

Thursday September 3, 2015 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, Zertane, RedoxSYS, ProstaScint

Aytu to acquire rights to Jazz Pharmaceuticals’ ProstaScint prostate detection drug

Aytu to acquire rights to Jazz Pharmaceuticals’ ProstaScint prostate detection drug

ENGLEWOOD-- Aytu BioScience Inc. (OTCMKTS: RSWN), a specialty health care company focused on developing treatments for urological and related conditions, today announced it entered into an... Read More

By: InnovatioNews Tuesday June 9, 2015 0 comments Tags: Englewood, Aytu BioScience, Jazz Pharmaceuticals, Josh Disbrow, ProstaScint, Zertane, RedoxSYS